QGEN Earnings Date: Nov 4, 2026 (Estimated) — Qiagen N.V.
NYSE · Healthcare · Diagnostics & Research
Updated
When is QGEN's next earnings date?
Qiagen N.V. (QGEN) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.63 on revenue of $538.6M.
How did QGEN do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Qiagen N.V. posted EPS of $0.62 versus the $0.60 estimate, a beat of 3.3%. Revenue was $535.0M against a $527.5M estimate. The stock's 1-day post-earnings move was -0.5%.
How much does QGEN stock move after earnings?
QGEN beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 2.0% (up or down) in the day after earnings.
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.60 | 0.62 | +3.33% | $535.0M | ✅ Beat | -0.52% | +2.50% | +4.55% |
| 2026-05-06 | Q1 2026 | 0.54 | 0.54 | +0.00% | $492.0M | ➖ Inline | -2.70% | -5.04% | +6.50% |
| 2026-02-04 | Q4 2025 | 0.62 | 0.62 | +0.00% | $540.0M | ➖ Inline | -0.94% | -1.27% | -13.85% |
| 2025-11-04 | Q3 2025 | 0.58 | 0.61 | +5.17% | $533.0M | ✅ Beat | -0.26% | +0.12% | +6.60% |
| 2025-08-05 | Q2 2025 | 0.60 | 0.60 | +0.00% | $534.0M | ➖ Inline | -4.92% | -1.97% | -5.84% |
| 2024-11-06 | Q3 2024 | 0.56 | 0.59 | +5.36% | $502.0M | ✅ Beat | +0.65% | -2.82% | -1.02% |
| 2024-07-31 | Q2 2024 | 0.53 | 0.57 | +7.55% | $496.0M | ✅ Beat | +2.93% | -0.10% | +2.66% |
| 2024-02-06 | Q4 2023 | 0.54 | 0.57 | +5.56% | $509.2M | ✅ Beat | -2.86% | -4.33% | -0.61% |
Showing last 8 quarters.
Revenue by segment & region
By segment
FY2025 · $4.18B total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Consumables and Related | 44.9% | $1.88B | — | $2.04B | — | — | — |
| Diagnostic Solutions | 19.2% | $803.1M | +7.2% | — | $460.8M | $638.8M | $660.9M |
| Sample Technologies | 15.8% | $661.3M | +3.0% | — | $803.9M | $850.6M | $796.9M |
| PCR / Nucleic Acid Amplification | 7.4% | $309.0M | +2.8% | — | $363.6M | $434.0M | $390.8M |
| Genomics / NGS | 5.8% | $241.8M | +3.5% | — | $165.6M | $245.1M | $224.8M |
| Instruments | 5.1% | $213.6M | — | $445.6M | — | — | — |
| Product and Service, Other | 1.8% | $74.9M | +40.7% | — | $76.6M | $83.2M | $68.1M |
By region
FY2025 · $3.18B total · annual
| Segment | Share | Revenue | YoY | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Total Americas | 34.2% | $1.09B | +5.3% | $722.0M | $825.5M | $1.01B | $997.8M |
| UNITED STATES | 31.4% | $998.4M | — | — | — | — | — |
| EMEA | 22.4% | $712.8M | +9.9% | $487.5M | $682.3M | $814.4M | $733.5M |
| Asia Pacific and Rest of World | 9.2% | $290.7M | -2.5% | $317.0M | $362.6M | $429.9M | $410.3M |
| Other Americas | 2.8% | $88.1M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.